Vilazodone	Placebo	Overall severity category shift from ≥ 4 to ≤ 2 	18282	18469	a significantly greater proportion of vilazodone-treated versus placebo-treated patients improved from baseline ≥ 4 (moderate to severe symptoms) to end of study ≤ 2 (mild to no symptoms)
Vilazodone	Placebo	Overall severity category shift from ≥ 4 to ≤ 2 	1395	1657	A significantly greater proportion of vilazodone-treated versus placebo-treated patients shifted from baseline ≥ 4 to end of study ≤ 2 on MADRS items of apparent sadness, reported sadness, inner tension, reduced sleep, and lassitude (OR range, 1.5–2.0, P < .05).
Vilazodone	Placebo	Abscense of anxious depression	1672	1867	a significantly greater proportion of vilazodone-treated versus placebo-treated patients shifted from anxious depression at baseline to no anxious depression at end of study (OR = 1.5, P = .031).
Vilazodone	Placebo	Severity category shift from ≥ 4 to ≤ 2 on the MADRS items of reduced appetite, concentration difficulties, inability to feel, and pessimistic thoughts	18482	18707	Between-group differences were not significant for reduced appetite (OR = 3.6, P = .074), concentration difficulties (OR = 1.5, P = .095), inability to feel (OR = 1.2, P = .468), and pessimistic thoughts (OR = 1.2, P = .465).
Vilazodone	Placebo	Severity category shift from ≥ 2 to < 2 on the reduced appetite MADRS item	17927	18027	the between-group difference was not significant for the reduced appetite item (OR = 1.3, P = .232).
